Barish Edil to Cancer Vaccines
This is a "connection" page, showing publications Barish Edil has written about Cancer Vaccines.
Connection Strength
0.682
-
Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clin Cancer Res. 2021 03 01; 27(5):1278-1286.
Score: 0.183
-
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015 Jan; 38(1):1-11.
Score: 0.121
-
A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol. 2014 Nov; 21(12):3931-7.
Score: 0.117
-
Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S725-30.
Score: 0.111
-
Vaccines for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):642-52.
Score: 0.104
-
Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One. 2011 Apr 29; 6(4):e19390.
Score: 0.024
-
Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surg Today. 2010 May; 40(5):404-10.
Score: 0.022